This case emphasizes the importance of further research to elucidate the specific mechanisms of primary resistance to ALK TKIs in non-canonical ALK fusion partners like KLC1. Developing targeted therapies for such rare cases is a clinical challenge that warrants continued investigation and innovation in...
Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: A case report. Cancer Biol. Med. 2017, 14, 183-186. [CrossRef]Wang, P.; Xiao, P.; Ye, Y.N.; Liu, P.P.; Han, L.; Dong, L.; ...